Profile data is unavailable for this security.
About the company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
- Revenue in USD (TTM)8.91m
- Net income in USD-80.74m
- Incorporated2013
- Employees100.00
- LocationVerrica Pharmaceuticals Inc10 N High St Ste 200WEST CHESTER 19380-3014United StatesUSA
- Phone+1 (484) 453-3300
- Fax+1 (302) 636-5454
- Websitehttps://verrica.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerus Corp | 191.72m | -31.56m | 356.84m | 288.00 | -- | 7.22 | -- | 1.86 | -0.1742 | -0.1742 | 1.06 | 0.2671 | 0.9623 | 1.92 | 8.03 | 665,680.60 | -15.91 | -25.99 | -24.20 | -40.62 | 61.73 | 61.90 | -16.53 | -35.81 | 1.72 | -2.16 | 0.6287 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 358.20m | 275.00 | -- | 0.6559 | -- | 1.29 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Jasper Therapeutics Inc | 0.00 | -63.93m | 359.34m | 45.00 | -- | 3.17 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Shattuck Labs Inc | 2.72m | -85.08m | 362.81m | 75.00 | -- | 2.81 | -- | 133.63 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 363.98m | 402.00 | -- | 2.99 | -- | 31.98 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Replimune Group Inc | 0.00 | -215.79m | 364.03m | 331.00 | -- | 0.9725 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Fractyl Health Inc | 148.00k | -83.16m | 364.97m | 102.00 | -- | 4.34 | -- | 2,466.04 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
| OraSure Technologies, Inc. | 304.64m | 22.85m | 373.49m | 638.00 | 16.61 | 0.8762 | 8.72 | 1.23 | 0.304 | 0.304 | 4.11 | 5.76 | 0.6573 | 2.77 | 4.31 | 477,493.70 | 4.93 | 0.7238 | 5.42 | 0.8212 | 45.26 | 46.94 | 7.50 | 1.13 | 10.49 | -- | 0.0017 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Organogenesis Holdings Inc | 435.47m | 5.82m | 373.85m | 862.00 | 64.86 | 1.34 | 17.61 | 0.8585 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Anika Therapeutics Inc | 169.26m | -76.83m | 376.79m | 357.00 | -- | 1.81 | -- | 2.23 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 380.89m | 40.00 | -- | 2.79 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 383.54m | 66.00 | -- | 1.62 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 383.90m | 100.00 | -- | 254.58 | -- | 43.07 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Cibus Inc | 2.32m | -285.67m | 392.54m | 183.00 | -- | 1.20 | -- | 169.20 | -18.29 | -18.29 | 0.1522 | 13.24 | 0.0084 | -- | -- | 12,677.60 | -129.84 | -86.28 | -147.90 | -96.45 | -- | -- | -15,483.49 | -792.07 | -- | -3.17 | 0.0039 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 399.07m | 145.00 | -- | 1.54 | -- | 19.92 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Contineum Therapeutics Inc | 50.00m | 22.72m | 407.97m | 31.00 | 17.54 | -- | 17.77 | 8.16 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Verrica Pharmaceuticals Inc's reporting currency: US Dollar USD
38.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Mar 2024 | 7.10m | 16.74% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 4.00m | 9.43% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.51m | 3.56% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.23m | 2.89% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.01m | 2.38% |
| Geode Capital Management LLCas of 31 Mar 2024 | 449.31k | 1.06% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 412.60k | 0.97% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 198.72k | 0.47% |
| BML Capital Management LLCas of 31 Mar 2024 | 180.00k | 0.42% |
| DWS Investment Management Americas, Inc.as of 31 Mar 2024 | 174.81k | 0.41% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
